Redirecting to original paper in 30 seconds...
Click below to go immediately or wait for automatic redirect
📄 Abstract
Abstract: Predicting interspecies interactions is a key challenge in microbial ecology,
as these interactions are critical to determining the structure and activity of
microbial communities. In this work, we used data on monoculture growth
capabilities, interactions with other species, and phylogeny to predict a
negative or positive effect of interactions. More precisely, we used one of the
largest available pairwise interaction datasets to train our models, comprising
over 7,500 interactions be- tween 20 species from two taxonomic groups
co-cultured under 40 distinct carbon conditions, with a primary focus on the
work of Nestor et al.[28 ]. In this work, we propose Graph Neural Networks
(GNNs) as a powerful classifier to predict the direction of the effect. We
construct edge-graphs of pairwise microbial interactions in order to leverage
shared information across individual co-culture experiments, and use GNNs to
predict modes of interaction. Our model can not only predict binary
interactions (positive/negative) but also classify more complex interaction
types such as mutualism, competition, and parasitism. Our initial results were
encouraging, achieving an F1-score of 80.44%. This significantly outperforms
comparable methods in the literature, including conventional Extreme Gradient
Boosting (XGBoost) models, which reported an F1-score of 72.76%.
Key Contributions
Proposes using Graph Neural Networks (GNNs) to predict the direction (positive or negative effect) of interspecies microbial interactions. By constructing edge-graphs of pairwise interactions and leveraging data on growth capabilities, phylogeny, and existing interactions, the GNN model effectively predicts interaction modes, offering insights into microbial community dynamics.
Business Value
Enables better understanding and prediction of microbial community behavior, leading to applications in areas like synthetic biology, environmental monitoring, and microbiome-based therapeutics.